What is ONE Rx?

The opioid misuse crisis has swept across the U.S. and our communities in the past decade. As many as one in four patients receiving long-term opioid therapy in a primary care setting struggles with opioid addiction. 1,2,3

It is important that opioid misuse prevention be moved upstream, to the initial patient encounter. In response to this challenge, faculty members at the NDSU School of Pharmacy and other partners introduced ONE Rx, a three-hour continuing education seminar and patient care process.

The purpose is to equip pharmacists with tools to screen for opioid use disorder to identify patient needs and provide counseling and support to assist them in safely using prescribed opioids.

Opioids can slow or stop your ability to breathe. Naloxone can reverse the effects of the opioids, and restore the ability to breathe.

It’s a safety measure, similar to a fire extinguisher. It’s good to have available, but hopefully you never need to use it.

One Rx is using the REDCap secure web application for data collection. REDCap meets HIPAA security requirements. It allows for multiple ways to collect data and provide real time reporting.

You can read the Manual and watch the Video Demonstration.

Learn more about the beginning of ONE Rx at North Dakota State University.

Stay up-to-date on the latest ONE Rx news with our monthly newsletters.

ONE Rx Training Includes:

  • The science of addiction
  • An introduction to a tool to screen patients for risk of opioid misuse4
  • Risks associated with accidental opioid overdose
  • Naloxone prescribing, dispensing and consulting
  • Consultation on the risk of opioid misuse exemplified through lecture and role-play
  • A list of support services in the community for individuals concerned about an opioid use disorder is provided to pharmacists to disseminate to patients
Acknowledgements: Funding for the design and delivery of the ONE Rx and pilot was provided by the North Dakota Department of Human Services, Alex Stern Family Foundation, ND Blue Cross Blue Shield Caring Foundation, FM Area Foundation, and the ND Board of Pharmacy.
  1. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. Drug Alcohol Depend 2009;104:34–42.
  2. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010;105:1776–82.
  3. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8:573–82.
  4. Webster LR, Webster R. Predicting aberrant behaviors in Opioid-treated patients: preliminary validation of the Opioid risk tool. Pain Med. 2005;6(6):432.
NDSU does not discriminate in its programs and activities on the basis of age, color, gender expression/identity, genetic information, marital status, national origin, participation in lawful off-campus activity, physical or mental disability, pregnancy, public assistance status, race, religion, sex, sexual orientation, spousal relationship to current employee, or veteran status, as applicable. Direct inquiries to: Vice Provost, Title IX/ADA Coordinator, Old Main 201, 701-231-7708, ndsu.eoaa@ndsu.edu.